CF Foundation Invests Up to $2 Million in Nanite Inc. to Explore a New Method to Deliver Genetic Therapies to the Lung

Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.

| 2 min read

The Cystic Fibrosis Foundation is investing up to $2 million in Nanite Inc. to explore a new way to deliver genetic therapies into the lung — delivery is one of the most significant challenges in creating a transformative treatment for all people with cystic fibrosis.

Nanite will be using artificial intelligence to narrow down the best polymer nanoparticle candidates. Nanite researchers believe they can program polymer nanoparticles to more accurately target lung cells and potentially better resist the thick, sticky mucus that clogs the lungs of people with CF.

At first, Nanite will work on developing polymer nanoparticles that can deliver messenger RNA therapy into the lungs. Eventually, Nanite hopes these nanoparticles can be used to deliver any type of genetic therapy and target other organs affected by CF, such as the pancreas.

The Foundation believes this early-stage research will help determine the feasibility of using polymer nanoparticles for CF. This investment is part of the Foundation’s $500 million Path to a Cure, an ambitious research initiative to accelerate treatments for everyone with CF and ultimately deliver a cure.

Share this article
Topics
Our Research Approach
Recent news
CF Foundation Establishes Health Equity Awards to Advance Research Toward Optimal Health Outcomes
News | 5 min read
CF Foundation Honors the Legacy of Joe O’Donnell
News | 4 min read
CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 
News | 2 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe